Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 1783916.
- Also identified by PMC identifier 1014678.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effectiveness of intranasal neostigmine (9.3-13.8 mg) was tested in 20 subjects with myasthenia gravis, classified as Osserman grades 2A and 2B. In all cases the drug produced significant clinical and electromyographic improvement. No side effects were reported during the treatment.
Medical subject headings
- Myasthenia Gravis
- Neostigmine